In conclusion, we showed that deleting Lcn2, genetically or blocking its activity with a monoclonal antibody, in the MDX mouse model of DMD is able to prevent or revert the bone loss induced by this disease. This evidence concerns the gene LCN2 and Duchenne muscular dystrophy.